Institutionalization of reconstructive lymphedema surgery in Austria—Single center experience

Chieh-Han John Tzou MD1,2,3 | Johannes Steinbacher MD1 | Manon Czedik-Eysenberg MD1,4 | Silvia Brandstaetter MD5 | Stefan Meng MD6,7 | Matthias Schuetz MD8 | Lisa Macho MD9 | Brigitte Obermayer MD4 | Viktor Grablowitz MD4 | Christoph Ausch MD4 | Ming-Huei Cheng MD10 | Joon Pio Hong MD, PhD11

1Plastic and Reconstructive Surgery, Department of Surgery, Hospital of Divine Savior, Vienna, Austria
2Faculty of Medicine, Sigmund Freud University, Vienna, Austria
3Lymphedema Center Vienna, Tzou Medical, Vienna, Austria
4Department of Surgery, Hospital of Divine Savior, Vienna, Austria
5Institute for Physical Medicine and Rehabilitation, Hanusch Hospital, Vienna Regional Health Insurance Fund (Wiener Gebietskrankenkasse-WGKK), Vienna, Austria
6Department of Radiology, KFJ Hospital, Vienna, Austria
7Center for Anatomy and Cell Biology, Medical University of Vienna, Vienna, Austria
8Institute of Radiology and Nuclear Medicine, Hanusch Hospital, Vienna Regional Health Insurance Fund (Wiener Gebietskrankenkasse-WGKK), Vienna, Austria
9Physical Medicine and Rehabilitation, Hospital of Divine Savior, Vienna, Austria
10Division of Reconstructive Microsurgery, Department of Plastic and Reconstructive Surgery, Chang Gung Memorial Hospital, College of Medicine, Chang Gung University, Taoyuan, Taiwan
11Department of Plastic Surgery, Asan Medical Center, University of Ulsan College of Medicine, Seoul, South Korea

Abstract

Background: Lymphedema surgery was not widely known in Austria before the introduction of lymphovenous anastomosis (LVA) and vascularized lymph node transfer (VLNT) in 2014. This study shares the experience and process of establishing and institutionalizing lymphedema surgery service in Austria.

Methods: The purpose of introducing reconstructive lymphedema surgery in Austria was to improve lymphedema patients’ quality of life and provide them surgical therapy as an adjuvant treatment to complete decongestive therapy. To initialize reconstructive lymphedema surgery in Austria, LVA and VLNT had to be presented and introduced, in the manner of branding and advertizing a new product. Surgeries were performed with quality control by standardized documentation, pre- and postoperatively.

Results: Aligned with branding and marketing, presentations were given externally and internally to share knowledge and experience of lymphedema surgery. Lymphedema surgery service was introduced as a new brand in the medical service in Austria. After several communications with the Austrian Health Insurance Fund and with the final application, LVA and VLNT were listed as novel surgical therapies in its 2020 reimbursement catalog. Since 2014, more than 300 lymphedema patients were consulted, and 102 reconstructive lymphedema surgeries were performed. Circumference reduction of extremities after surgery was between 20% and 43%, postoperatively.

Conclusion: Acceptance of surgery in lymphedema patients varies among continents, hospitals, and surgeons. Evaluation of the requirement of the surgical setup and insurance conditions for lymphedema surgery is essential to establish lymphedema surgery, providing targeted marketing and branding to spread knowledge of the novel technique and grant patients access to therapeutic treatment of their chronic disease.

KEYWORDS: CDT, complete decongestive therapy, flagship, lymphedema surgery center, lymphovenous anastomosis LVA, market introduction, branding, vascularized lymph node transfer VLNT